Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17817590 | 1.00 | ADORA2A (0.64) | ADORA2ACYP2C9LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL2656868 | 0.98 | ADORA2A (0.66) | ADORA2ACYP2C9LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL1854243 | 0.94 | ADORA2A (0.71) | ADORA2ACYP2C9LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL15480447 | 0.92 | ALDH1A1 (0.67) | LMNAALDH1A1HPGDNPSR1SMN1; SMN2 | |
| SCHEMBL15480448 | 0.92 | ALDH1A1 (0.67) | LMNAALDH1A1HPGDNPSR1SMN1; SMN2 | |
| SCHEMBL15480445 | 0.92 | ALDH1A1 (0.67) | LMNAALDH1A1HPGDNPSR1SMN1; SMN2 | |
| SCHEMBL15480450 | 0.92 | ALDH1A1 (0.67) | LMNAALDH1A1HPGDNPSR1SMN1; SMN2 | |
| SCHEMBL15480444 | 0.91 | ALDH1A1 (0.68) | LMNAALDH1A1HPGDNPSR1SMN1; SMN2 | |
| SCHEMBL1860388 | 0.90 | L3MBTL1 (0.56) | ADORA2ACYP2C9LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL1868857 | 0.90 | L3MBTL1 (0.56) | ADORA2ACYP2C9LMNAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216440-A1 | Process for preparing arylacetylaminothiazoles | CHEN BANG-CHI (US) | 2003-11-20 | — | — | US | disclosed |
| US-6613911-B2 | Reaction of haloarylacetic acids or esters with olefins to give vinylarylacetic acids or esters, oxidation with an oxidizing reagent gives formylarylacetic acids or esters | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-02 | — | — | US | disclosed |
| EP-1303512-A1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | Bristol-Myers Squibb Company (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20020072609-A1 | Process for preparing arylacetylaminothiazoles | CHEN BANG-CHI (US) | 2002-06-13 | — | — | US | disclosed |
| US-6392053-B2 | INCLUDES REACTING HALOARYLACETIC ACIDS OR ESTERS WITH OLEFINS TO GIVEN VINYLACRYLACETIC ACIDS OR ESTERS, FOLLOWED BY OXIDATION TO FORM THE FORMYLARYLACETIC ACID INTERMEDIATE; CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-21 | — | — | US | disclosed |
| WO-2002010161-A1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-07 | — | — | WO | disclosed |
| US-20010004639-A1 | Process for preparing arylacetylaminothiazoles | BRISTOL-MYERS SQUIBB COMPANY | 2001-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216440-A1 | Process for preparing arylacetylaminothiazoles | CCNI, CCNT1, CCNA1 | ADORA2A 1742/4885CYP2C9 196/4885LMNA 2351/4885 |
| US-20020072609-A1 | Process for preparing arylacetylaminothiazoles | CCNT1, CCNI, CCNA1 | ADORA2A 1896/4885CYP2C9 175/4885LMNA 2630/4885 |
| US-20010004639-A1 | Process for preparing arylacetylaminothiazoles | CCNI, CCNA1, CCNT1 | ADORA2A 1807/4885CYP2C9 231/4885LMNA 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.